Overview of the clinical results of pentasaccharide in major orthopedic surgery

Haematologica

Volumn 86, Issue 11 SUPPL. 2, 2001, Pages 59-62

  Turpie, Alexander G G ^a  

^a HHS General Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; PENTASACCHARIDE;

BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORTHOPEDIC SURGERY; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

CLINICAL TRIALS, PHASE III; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; POLYSACCHARIDES; SURVIVAL RATE; THERAPEUTIC EQUIVALENCY; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 0035702726     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Prevention of venous thromboembolism
2. Chemical synthesis of glycosaminoglycans: New approaches to antithrombotic drugs
3. The unique antithrombin III binding domain of heparin: A lead to new synthetic antithrombotics
4. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
5. The effect of the synthetic pentasaccharide SR 90107/Org 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa
6. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity
7. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
8. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR9017A/ORG31540) with pure anti-factor Xa activity a phase II evaluation
9. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction. The PENTALYSE study
10. The EPHESUS Study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) the prevention of venous thromboembolism (VTE) after elective hip replacement
11. The PENTATHLON 2000 study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
12. The PENTAMAKS study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thromboembolism (VTE) after elective major knee surgery
13. The PENTHIFRA study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after hip fracture surgery